Scope launches two revolutionary drugs

Pharmacia and Upjohn has chosen Scope Ketchum to promote two new products - Edronax (reboxetine), a new anti-depressant and Cabaser (cabergoline), a treatment for Parkinson’s disease.

Pharmacia and Upjohn has chosen Scope Ketchum to promote two new

products - Edronax (reboxetine), a new anti-depressant and Cabaser

(cabergoline), a treatment for Parkinson’s disease.



Scope Ketchum won the accounts, which together are likely to bring in a

six-figure fee, after a non-competitive pitch.



Pharmacia and Upjohn marketing director, Mike Berridge, said: ’Scope

came on board initially for the Parkinson’s disease work, but the

quantity of senior level expertise gave us the confidence to award them

our Edronax business.’



Edronax is a noradrenaline reuptake inhibitor. ’Older tricyclics were

not selective and this meant that patients suffered from numerous side

effects, like sleepiness,’ said Karen Winterhalter, account director at

Scope Ketchum. ’Edronax is more selective, so there are fewer side

effects.’



The agency will be conducting a pre-marketing campaign, presenting

Edronax to psychiatrists at national meetings throughout the summer.



Cabaser is the first once daily dopamine agonist which is used in

conjunction with levadopa to control motor functions and prevent

shaking.



’Some patients can be taking tablets every couple of hours and the drugs

dominate their existence,’ said Winterhalter. ’One tablet of Cabaser

taken once a day can change their lives.’



Other Scope Ketchum healthcare clients include Acuson, Bayer, Janssen

and Dow Chemical.



Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

Max Clifford trial jury to continue deliberations after Easter break

Max Clifford trial jury to continue deliberations after Easter break

The jury in the trial of celebrity publicist Max Clifford has been sent home for Easter and will reconvene on Tuesday for further deliberations about its verdicts on 11 charges of indecent assault.

Home Office brings in Munro & Forster to campaign against FGM

Home Office brings in Munro & Forster to campaign against FGM

The Home Office has tasked Munro & Forster (M&F) with supporting its campaign to eradicate female genital mutilation (FGM) as part of a wider retained brief.

Former White House press secretary Dee Dee Myers to join Warner Bros

Former White House press secretary Dee Dee Myers to join Warner Bros

Warner Bros has appointed former White House press secretary Dee Dee Myers as EVP for worldwide corporate communications and public affairs, effective September 2.

Edelman takes a ride on Branson's slow-motion space adventure

Edelman takes a ride on Branson's slow-motion space adventure

Virgin Galactic is probably on every PR agency's dream assignment list, but previous delays to Richard Branson's space venture suggest it may not be a complete blast.